MEGAN LEGENDRE: Open Payments
NPI 1316402969 · RESERVE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,577 in 136 payments from 16 companies in 2025. Trend: 2023 $1,193 · 2024 $2,204 · 2025 $2,577
Food & beverage: $2,516Education: $61
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $636 |
| Madrigal Pharmaceuticals | 20 | $555 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $246 |
| Janssen Biotech, Inc. | 11 | $220 |
| Gilead Sciences, Inc. | 9 | $147 |
| Phathom Pharmaceuticals, Inc. | 10 | $134 |
| Ardelyx, Inc. | 7 | $127 |
| GlaxoSmithKline, LLC. | 1 | $104 |
| GENZYME CORPORATION | 4 | $91 |
| Novo Nordisk Inc | 3 | $71 |
Products named: REZDIFFRA, SKYRIZI, RINVOQ, ENTYVIO, TREMFYA, VOQUEZNA, DUPIXENT, IBSRELA.
Industry payments across LA — which companies pay providers there.
